GlaxoSmithKline Pharmaceuticals Ltd (GLAXO) – Share Price & Analysis

Price ₹2199.80, Market Cap 42.32K (Cr), P/E 44.39x. Score: 58.7/100.

Financial Ratios PE Ratio Shareholding Dividend Quarterly Results Financial Statements

GlaxoSmithKline Pharmaceuticals Ltd Stock Price Today (NSE: GLAXO)

GlaxoSmithKline Pharmaceuticals Ltd

GLAXOPharmaceuticals

₹2199.80₹3.00 (0.14%)

As on 17 Jun 2026, 01:05 pm ISTMarket Closed

Fundamental Score

...

GlaxoSmithKline Pharmaceuticals Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

GlaxoSmithKline Pharmaceuticals Ltd share price today is ₹2199.80, down 0.14% on NSE/BSE as of 17 June 2026. GlaxoSmithKline Pharmaceuticals Ltd (GLAXO) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹42.32K (Cr). The 52-week high for GLAXO share price is ₹3500.00 and the 52-week low is ₹2154.00. At a P/E ratio of 44.39x, GLAXO is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 46.87% and a debt-to-equity ratio of 0.02.

GlaxoSmithKline Pharmaceuticals Ltd Share Price Chart — NSE/BSE Historical Performance

No data

High

₹2520.00

Low

₹2199.80

Volume

1.0L

Change

-5.86%

GlaxoSmithKline Pharmaceuticals Ltd — Last 10 Trading Days

Date	Open	High	Low	Close	Volume
2 Jun 26	₹2204.30	₹2204.30	₹2154.00	₹2188.80	92.99K (Cr)
1 Jun 26	₹2200.00	₹2219.90	₹2183.20	₹2204.40	81.11K (Cr)
29 May 26	₹2259.90	₹2267.00	₹2194.40	₹2210.20	3.04L (Cr)
28 May 26	₹2239.20	₹2239.20	₹2239.20	₹2239.20	0.00 (Cr)
27 May 26	₹2295.00	₹2315.90	₹2283.20	₹2296.20	1.79L (Cr)
26 May 26	₹2300.10	₹2314.40	₹2278.10	₹2282.40	1.56L (Cr)
25 May 26	₹2329.00	₹2341.00	₹2297.00	₹2300.10	1.11L (Cr)
22 May 26	₹2330.00	₹2344.00	₹2297.00	₹2306.90	1.85L (Cr)
21 May 26	₹2379.00	₹2379.20	₹2314.00	₹2320.70	1.06L (Cr)
20 May 26	₹2388.00	₹2397.80	₹2340.10	₹2346.80	80.19K (Cr)

GlaxoSmithKline Pharmaceuticals Ltd — Last 12 Months Price History

Month	Open	High	Low	Close	Change
Jun 2026	₹2200.00	₹2219.90	₹2154.00	₹2188.80	-0.51%
May 2026	₹2342.00	₹2520.00	₹2194.40	₹2210.20	-5.63%
Apr 2026	₹2305.00	₹2529.90	₹2261.90	₹2336.40	+1.36%
Mar 2026	₹2520.00	₹2581.60	₹2217.60	₹2283.00	-9.40%
Feb 2026	₹2400.20	₹2719.80	₹2342.10	₹2571.60	+7.14%
Jan 2026	₹2476.00	₹2528.00	₹2220.30	₹2401.60	-3.00%
Dec 2025	₹2551.00	₹2635.00	₹2362.60	₹2473.60	-3.03%
Nov 2025	₹2644.00	₹2694.00	₹2404.20	₹2569.50	-2.82%
Oct 2025	₹2659.70	₹2795.90	₹2601.00	₹2618.60	-1.55%
Sept 2025	₹2786.00	₹2883.40	₹2622.60	₹2659.70	-4.53%
Aug 2025	₹3162.90	₹3184.30	₹2560.00	₹2785.00	-11.95%
Jul 2025	₹3388.70	₹3450.00	₹3072.50	₹3162.60	-6.67%

AI Research Briefing

GSK's expensive pivot to specialty pharma needs flawless execution to justify its premium valuation.

Research Confidence

6.0/10Moderate

COMPOUNDERBreakdown - 1M: -4.7%, 3M: -9.33%, 6M: -27.04%Expensive - P/E of 44.39x vs industry P/E of 31.77x

WHAT'S HAPPENING NOW (last 2-4 weeks)

No major catalysts found after live search. GlaxoSmithKline Pharmaceuticals Ltd submitted its Q4FY26 compliance certificate to stock exchanges.

CORE STORY (THE REAL GAME)

GlaxoSmithKline (GSK) is pivoting towards specialty pharmaceuticals, particularly in oncology and respiratory, while maintaining its base in general medicines. The market is pricing in GSK's ability to successfully transition to higher-margin specialty products and maintain growth amidst global pricing pressures.

WHAT IS DRIVING THE STOCK

Specialty Medicines Growth: GSK's focus on specialty medicines, with sales reaching £13.5B in 2025 (+17%), is a key driver. Oncology sales grew by 43% to £2.0B, and Respiratory, Immunology & Inflammation (RI&I) grew by 18% to £3.8B.

Acquisitions: GSK has been actively acquiring companies to bolster its pipeline in oncology and RI&I. Recent acquisitions include 35Pharma for $950M and RAPT Therapeutics for $2.2B.

Dividend Increase: GSK has declared an increased dividend for 2025 of 66p per share and expects 70p per share for 2026, signaling confidence in its financial performance.

BULL vs BEAR

Bull:GSK's focus on specialty medicines and strategic acquisitions will drive long-term growth and profitability. The company's strong financial performance and commitment to shareholder returns make it an attractive investment.

Bear:GSK faces challenges from supply chain disruptions, regulatory dynamics, and declining growth in general medicines. The high P/E ratio of 44.39x compared to the industry P/E of 31.77x suggests that the stock may be overvalued. Currency fluctuations could also negatively impact earnings.

WHAT MARKET IS PRICING

The market is pricing in continued growth in specialty medicines and successful integration of recent acquisitions. If GSK fails to deliver on these expectations, the stock could face a correction.

BOTTOM LINE

GSK is betting big on specialty pharma, but rich valuation and execution risks demand caution.

Why Now

Focus on specialty medicines driving growth
Strategic acquisitions bolstering pipeline
Increased dividend signaling financial confidence

Potential Catalysts

Successful commercial launches of new specialty drugs
Positive results from pivotal clinical trials
Further strategic acquisitions to expand pipeline

Key Risks

High P/E ratio compared to industry average
Declining growth in general medicines
Currency fluctuation risks

Institutional Activity

FII decreased their holdings by 0.1%, while DII increased their holdings by 0.04%. Promoter holding remains unchanged at 75.0%.

Macro Context

Indian pharmaceutical exports are projected to reach $130 billion by 2030, providing a tailwind for GSK's India operations.

Cash Flow Quality

Yes - Free Cash Flow 5Y: ₹5204.49 Cr

3–6 Month Outlook

GSK's 3-6 month thesis hinges on successful commercial launches and positive clinical trial results. Failure to execute could lead to a significant correction.

Primary Thesis Risk

Failure to successfully transition to specialty pharmaceuticals will decimate the growth story.

For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.

Returns & Performance

Excellent

Return on Equity (ROE)

46.87%

Profit generated per ₹1 of shareholder equity

Excellent

Return on Capital (ROCE)

63.25%

Returns generated on total capital deployed

Excellent

Oper. Profit Margin (5Y Avg)

25.52%

Average operating profit margin over 5 years

Good

Dividend Yield

1.68%

Annual dividend as % of current share price

GlaxoSmithKline Pharmaceuticals Ltd Valuation Check

Poor

Price to Earnings (P/E)

44.39x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

31.77x

Average P/E of all peers in this sector

Market-cap Classification

Large-cap

Established & liquid; typically steadier returns.

Market Capitalisation

42.32K (Cr)

Total market value of all outstanding shares

Shareholding Pattern

Excellent

Promoter Holding

75.00%

% shares held by company founders/management

Poor

FII Holding

4.79%

% shares held by foreign institutional investors

Average

DII Holding

7.75%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Poor

Profit Growth (Quarterly YoY)

2.57%

Net profit growth vs same quarter last year

Poor

Revenue Growth (Quarterly YoY)

-3.05%

Revenue growth vs same quarter last year

Poor

Revenue Growth (5-Year CAGR)

3.06%

Compounded annual revenue growth over 5 years

Excellent

EPS Growth (5-Year CAGR)

34.71%

Earnings per share growth over 5 years

Excellent

Net Profit Growth (5-Year CAGR)

34.71%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.02x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

811.63x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

5.20K (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

GlaxoSmithKline Pharmaceuticals Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of GLAXO across key market metrics for learning purposes.

Positive Indicators

10 factors identified

Strong Return on Equity (46.87%)

Observation: Efficient use of shareholders' capital generating superior returns.

Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.

Excellent ROCE Performance (63.25%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.

Strong Operating Margins (25.52%)

Observation: Healthy 5-year operating margins indicate pricing power and cost control.

Analysis: OPM >15% suggests operational efficiency and competitive advantages.

Excellent EPS Growth (34.71% CAGR)

Observation: Outstanding 5-year earnings per share compound growth.

Analysis: EPS CAGR >15% indicates strong wealth creation potential.

Strong Profit Growth Track Record (34.71% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model.

Conservative Debt Levels (D/E: 0.02)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Strong Interest Coverage (811.63x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Strong Cash Generation (₹5204.49 Cr over 5Y)

Observation: Healthy free cash flow generation supports growth and returns.

Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.

Balanced Promoter Holding (75.00%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

2 factors identified

Premium Valuation Risk (P/E: 44.39x)

Observation: High valuation multiples may limit upside potential.

Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.

Limited Growth History (3.06% CAGR)

Observation: Below-average 5-year sales growth trajectory.

Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.

GlaxoSmithKline Pharmaceuticals Ltd vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare GlaxoSmithKline Pharmaceuticals Ltd with 10 other companies in the same sector

11 companies

Company Info	Fundamental Overall score	Valuation Price metrics	Profitability Return metrics		Financial Health Debt management	Growth 5Y performance		Dividend Yield %
Company Company name	Score Bull Run comprehensive fundamental score based on 20+ metrics	Price Current trading price of the stock	Market Cap Total value of all shares in the market	P/E Price per share divided by earnings per share	ROE Net income divided by shareholder equity	ROCE Earnings before interest and tax divided by capital employed	Debt/Eq Total debt divided by total equity	Profit 5Y Average annual profit growth over 5 years	Sales 5Y Average annual sales growth over 5 years	Dividend Annual dividend per share divided by price per share
GlaxoSmithKline Pharmaceuticals LtdGlaxoSmithKline...Selected✓ GLAXO • 500660	58.7/100	₹2199.80₹2200	₹42320.52₹42320.52	44.39Average 44.4 Average	46.87%Excellent 46.87% Excellent	63.25%Excellent 63.25% Excellent	0.02Excellent 0.0 Excellent	34.71%Excellent 34.71% Excellent	3.06%Average 3.06% Average	1.68%
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715	65.2/100	₹1882.30₹1882	₹433738.68₹433738.68	37.57Average 37.6 Average	16.86%Good 16.86% Good	20.21%Excellent 20.21% Excellent	0.07Excellent 0.1 Excellent	23.78%Excellent 23.78% Excellent	9.87%Good 9.87% Good	0.89%
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488	67.9/100	₹6797.50₹6798	₹170445.88₹170445.88	68.59Average 68.6 Average	15.35%Good 15.35% Good	20.44%Excellent 20.44% Excellent	0.01Excellent 0.0 Excellent	10.41%Good 10.41% Good	11.65%Good 11.65% Good	0.47%
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420	65.3/100	₹4460.10₹4460	₹126430.62₹126430.62	58.36Average 58.4 Average	26.52%Excellent 26.52% Excellent	27.05%Excellent 27.05% Excellent	0.33Excellent 0.3 Excellent	13.84%Good 13.84% Good	7.72%Good 7.72% Good	0.86%
Cipla LtdCipla Ltd... CIPLA • 500087	59/100	₹1418.20₹1418	₹123059.76₹123059.76	22.62Average 22.6 Average	17.77%Good 17.77% Good	22.72%Excellent 22.72% Excellent	0.01Excellent 0.0 Excellent	28.68%Excellent 28.68% Excellent	9.97%Good 9.97% Good	0.85%
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124	59.2/100	₹1335.20₹1335	₹105224.96₹105224.96	18.23Average 18.2 Average	17.96%Good 17.96% Good	22.69%Excellent 22.69% Excellent	0.16Excellent 0.2 Excellent	22.28%Excellent 22.28% Excellent	13.26%Good 13.26% Good	0.63%
Lupin LtdLupin Ltd... LUPIN • 500257	66.7/100	₹2287.40₹2287	₹95148.15₹95148.15	22.00Average 22.0 Average	20.62%Excellent 20.62% Excellent	21.30%Excellent 21.30% Excellent	0.32Excellent 0.3 Excellent	54.88%Excellent 54.88% Excellent	8.11%Good 8.11% Good	0.58%
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321	68.7/100	₹956.95₹957	₹94253.78₹94253.78	18.74Average 18.7 Average	21.21%Excellent 21.21% Excellent	24.31%Excellent 24.31% Excellent	0.38Excellent 0.4 Excellent	25.92%Excellent 25.92% Excellent	10.27%Good 10.27% Good	1.17%
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904	50.6/100	₹2492.60₹2493	₹92012.53₹92012.53	52.62Average 52.6 Average	14.68%Average 14.68% Average	15.98%Good 15.98% Good	0.55Good 0.6 Good	11.73%Good 11.73% Good	15.79%Excellent 15.79% Excellent	0.04%
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804	28.8/100	₹1435.90₹1436	₹70798.69₹70798.69	20.69Average 20.7 Average	11.08%Average 11.08% Average	14.18%Average 14.18% Average	0.22Excellent 0.2 Excellent	3.87%Average 3.87% Average	6.55%Good 6.55% Good	0.33%
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523	59.5/100	₹5451.50₹5452	₹67075.29₹67075.29	28.54Average 28.5 Average	19.39%Good 19.39% Good	20.38%Excellent 20.38% Excellent	0.18Excellent 0.2 Excellent	13.93%Good 13.93% Good	9.21%Good 9.21% Good	0.80%

Top Pharmaceuticals Stocks

View all →

By Bull Run Score

By Return on Equity

Torrent Pharmaceuticals Ltd share price26.52%
Zydus Lifesciences Ltd share price21.21%
Lupin Ltd share price20.62%
Alkem Laboratories Ltd share price19.39%
Dr Reddys Laboratories Ltd share price17.96%

By Market Cap

Sun Pharmaceutical Industries Ltd share price433738.68 Cr
Divis Laboratories Ltd share price170445.88 Cr
Torrent Pharmaceuticals Ltd share price126430.62 Cr
Cipla Ltd share price123059.76 Cr
Dr Reddys Laboratories Ltd share price105224.96 Cr

GlaxoSmithKline Pharmaceuticals Ltd PE Ratio History

Historical price-to-earnings ratio for GLAXO — last 5 years

Year	EPS (₹)	Price (₹)	P/E Ratio
FY 2025	₹54.76	₹2473.60	45.2x
FY 2024	₹34.83	₹2251.85	64.7x
FY 2023	₹36.05	₹1898.15	52.7x
FY 2022	₹100.04	₹1318.75	13.2x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

GlaxoSmithKline Pharmaceuticals Ltd Dividend History

Annual cash dividends paid by GLAXO — dividend yield 1.68%

Financial Year	Dividends Paid (₹ Cr)
FY 2025	₹749.38 Cr
FY 2024	₹541.57 Cr
FY 2023	₹1525.50 Cr
FY 2022	₹506.63 Cr

Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.

GlaxoSmithKline Pharmaceuticals Ltd Quarterly Performance

Latest quarterly metrics for GLAXO — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

-3.05%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

2.57%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

3.06%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

34.71%

Compounded annual net profit growth over 5 years

GlaxoSmithKline Pharmaceuticals Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for GLAXO — calculated from daily price history

Oversold — RSI 18

Selling pressure is heavy — potential reversal zone.

SMA 50

₹2385

▼ Price below SMA 50 — Short-term bearish

SMA 200

₹2550

▼ Price below SMA 200 — Long-term downtrend

30-Day Avg Volume

88K shares/day

Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

GlaxoSmithKline Pharmaceuticals Ltd Financial Statements

Annual income statement, balance sheet and cash flow for GlaxoSmithKline Pharmaceuticals Ltd (GLAXO) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for GlaxoSmithKline Pharmaceuticals Ltd

About GLAXO (GlaxoSmithKline Pharmaceuticals Ltd)

GlaxoSmithKline Pharmaceuticals Ltd is a global healthcare powerhouse dedicated to the discovery, development, and manufacturing of innovative medicines and vaccines. With a legacy... spanning centuries, GSK focuses on addressing some of the world's most significant health challenges, ranging from infectious diseases and respiratory ailments to cancer and immune-related disorders. The company invests heavily in research and development, fostering a culture of scientific excellence and collaboration to accelerate the delivery of life-changing therapies. GSK's commitment extends beyond scientific innovation; it encompasses a deep-rooted dedication to ethical practices, sustainability, and improving global health equity. Through strategic partnerships and global initiatives, GSK strives to ensure that its medicines and vaccines reach those who need them most, regardless of geography or socioeconomic status. GSK's diverse product portfolio encompasses a wide range of therapeutic areas, offering solutions for prevention, treatment, and management of various medical conditions. Its vaccine division plays a crucial role in protecting individuals and communities from preventable diseases, with a strong emphasis on pediatric and adolescent immunization. From groundbreaking oncology drugs targeting specific cancer pathways to novel respiratory therapies designed to alleviate breathing difficulties, GSK's pharmaceuticals are making a tangible difference in the lives of patients worldwide. The company's commitment to innovation extends to its manufacturing processes, leveraging advanced technologies to optimize production efficiency and ensure the highest quality standards. Beyond its core business activities, GSK actively engages in corporate social responsibility initiatives, supporting programs that promote health education, access to healthcare, and community development. The company is dedicated to reducing its environmental impact and operates under stringent ethical guidelines to ensure transparency and accountability in all its operations. GSK recognizes that its success is intrinsically linked to the well-being of the communities it serves and strives to be a responsible corporate citizen, contributing to a healthier and more sustainable future. The firm’s focus is on developing and commercializing cutting-edge pharmaceutical products, which contributes to better patient outcomes.